Have a feature idea you'd love to see implemented?
Let us know!
TCRT Alaunos Therapeutics Inc
Price (delayed)
$2.2
Market cap
$3.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$18.6
Enterprise value
-$622,246
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12
Highlights
Alaunos Therapeutics's debt has plunged by 100% YoY
The company's quick ratio has surged by 52% YoY and by 8% QoQ
The revenue has plunged by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of TCRT
Market
Valuations
Earnings
Shares outstanding
1.6M
Market cap
$3.52M
Enterprise value
-$622,246
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
704.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-124.45
Revenue
$5,000
EBIT
-$25.71M
EBITDA
-$23.91M
Free cash flow
-$21.31M
Per share
Balance sheet
Liquidity
EPS
-$18.6
Free cash flow per share
-$13.31
Book value per share
$2.99
Revenue per share
$0
TBVPS
$3.77
Total assets
$6.04M
Total liabilities
$1.24M
Debt
$0
Equity
$4.8M
Working capital
$4.8M
Debt to equity
0
Current ratio
4.87
Quick ratio
3.34
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
-478,240%
Gross margin
100%
Net margin
-535,480%
Operating margin
-526,760%
Return on assets
-173.7%
Return on equity
-229.6%
Return on invested capital
-934%
Return on capital employed
-535.9%
Return on sales
-514,120%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TCRT stock price
How has the Alaunos Therapeutics stock price performed over time
Intraday
-7.95%
1 week
-0.45%
1 month
-34.33%
1 year
-85.36%
YTD
-79.25%
QTD
-31.68%
Financial performance
How have Alaunos Therapeutics's revenue and profit performed over time
Revenue
$5,000
Gross profit
$5,000
Operating income
-$26.34M
Net income
-$26.77M
Gross margin
100%
Net margin
-535,480%
The revenue has plunged by 100% YoY
The gross profit has dropped by 100% year-on-year
TCRT's net income is up by 30% year-on-year and by 24% since the previous quarter
The company's operating income rose by 26% YoY and by 23% QoQ
Growth
What is Alaunos Therapeutics's growth rate over time
Valuation
What is Alaunos Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
704.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-124.45
Alaunos Therapeutics's EPS has increased by 30% YoY and by 15% from the previous quarter
The price to book (P/B) is 86% lower than the 5-year quarterly average of 5.2 and 82% lower than the last 4 quarters average of 4.2
TCRT's equity has shrunk by 84% YoY and by 24% QoQ
The revenue has plunged by 100% YoY
The price to sales (P/S) is 75% lower than the last 4 quarters average of 2835.0
Efficiency
How efficient is Alaunos Therapeutics business performance
The company's return on assets has shrunk by 191% YoY and by 29% QoQ
The ROIC has shrunk by 155% YoY and by 27% QoQ
The return on equity has dropped by 112% year-on-year and by 17% since the previous quarter
Alaunos Therapeutics's ROS has increased by 23% from the previous quarter
Dividends
What is TCRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TCRT.
Financial health
How did Alaunos Therapeutics financials performed over time
Alaunos Therapeutics's current ratio has soared by 117% YoY and by 15% from the previous quarter
The total liabilities has plunged by 94% YoY and by 37% from the previous quarter
Alaunos Therapeutics's debt is 100% less than its equity
The debt to equity has dropped by 100% year-on-year
Alaunos Therapeutics's debt has plunged by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.